Duchenne Muscular Dystrophy (DMD)

DMD/BMD - James Ervasti, Ph.D.

James Ervasti, professor of biochemistry, molecular biology & biophysics at the University of Minnesota in Minneapolis, was awarded an MDA research grant totaling $390,000 over a period of three years to help support his research into improving two therapies currently in development for people with Duchenne (DMD) and Becker (BMD) muscular dystrophies.

DMD - Vladimir Ljubicic, Ph.D.

Vladimir Ljubicic, a postdoctoral fellow in the department of cellular and molecular medicine at the University of Ottawa in Ontario, Canada, was awarded an MDA development grant (DG) totaling $180,000 over a period of three years for his investigation into potential therapies for Duchenne muscular dystrophy (DMD).

DMD - Andrew Ho, Ph.D.

MDA has awarded a development grant totaling $180,000 over a period of three years to Andrew Ho, a postdoctoral fellow at the Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine in Stanford, Calif. The funds will help support Ho's study of human muscle stem cell regulation and the potential for stem-cell-based therapies in Duchenne muscular dystrophy (DMD).

MDA Funds Development of Utrophin 'Magnet' for DMD/BMD

 

Nationwide Children's Podcast Probes Exon Skipping in DMD

A January 2012 podcast from Nationwide Children's Hospital in Columbus, Ohio, explores the potential of a strategy called exon skipping as a treatment for Duchenne muscular dystrophy (DMD).

2011 Lexus GX-460 Premium

Artist: 
Dhruv Prasad

Dhruv began drawing pictures as a very young boy.  He especially enjoys drawing cars and Star Wars characters and playing robotics and video games.  His favorite school subjects are math and science.  This drawing was reversed from black on white to white on black.

MDA Funds Clinical Studies of Reformulated Drug for DMD

MDA has awarded $750,000 to Summit Corporation PLC for development and testing of SMT C1100, the company's experimental drug for treatment ofDuchenne muscular dystrophy (DMD). Summit is an Oxford, United Kingdom, drug discovery company.

The award was made through MDA's Venture Philanthropy (MVP) arm, a part of MDA's translational research program.

Podcast Explores Blocking NF-kappa B in DMD

A December 2011 podcast from Nationwide Children's Hospital in Columbus, Ohio, explores how an inhibitor of a protein called NF-kappa B has been beneficial in a mouse model of Duchenne muscular dystrophy (DMD) and is now being developed as a potential DMD treatment.

The podcast is part of a Nationwide Children's series called "This Month in Muscular Dystrophy."

Companies Expand Development of Exon Skipping for DMD

Two pharmaceutical companies recently announced they are expanding their development and testing of exon-skipping drugs for Duchenne muscular dystrophy (DMD).

CoQ10, Lisinopril Trial in DMD, BMD, LGMD2C-2F, LGMD2I

Researchers at five U.S. and one Canadian center are conducting a clinical trial of the medications coenzyme Q10 and lisinopril to determine their possible beneficial effects on heart function in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and five forms of limb-girdle muscular dystrophy (LGMD).

Pages

MDA in Your Community